Bayer to spend up to $4bn on Asklepios BioPharmaceutical
27-10-2020
Intercept sues Apotex over Ocaliva generic
26-08-2020
Senior counsel at Bayer highlights pharmaceutical TM challenges
15-03-2019
EPO revokes Bayer broccoli patent
09-11-2018
photobyphm / Shutterstock.com
Bayer Healthcare Pharmaceuticals has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents for cancer drug Stivarga (regorafenib).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bayer, Apotex, settle, suit, cancer, drug, patent, infringement, Stivarga, generics, regorafenib, Pharmaceuticals, settled
